PURPOSE: To report the optical coherence tomography angiography (OCT-A) findings in an exudative age-related macular degeneration (AMD) patient presenting mixed type I and II choroidal neovascularization (CNV) during follow-up after intravitreal vascular endothelial growth factor (VEGF) trap treatment. METHODS: The clinical assessment included both traditional multimodal imaging, based on fluorescein angiography (FA), indocyanine green angiography (ICGA) and B-scan OCT, and OCT-A at baseline and follow-up. OCT-A images were obtained using a Spectralis OCT-A prototype able to acquire 70,000 A-scans per second, with a resolution of 7 µm axially and 14 µm laterally. An amplitude decorrelation algorithm developed by Heidelberg Engineering was applied to a volume scan, on a 15 × 5° area, which was composed of 131 B-scans (35 frames per scan) at a distance of 11 µm each. The borders of type I and type II CNV were manually outlined and then the areas were analyzed using the provided automated software before and after treatment. RESULTS: The qualitative approach revealed a substantial decrease in the visibility of tiny branching vessels and anastomoses both in type I and type II components of the neovascular complex, associated with persistence of a clear hyperintense signal coming from the larger trunks, which remained well-perfused. Quantitative analysis confirmed a reduction of the lesion area after VEGF trap treatment: the type II component decreased from 0.25 to 0.19 mm(2), while the type I component decreased from 2.03 to 1.80 mm(2). CONCLUSIONS: Our study qualitatively and quantitatively demonstrated the response of a mixed type I-II CNV to intravitreal VEGF trap therapy. Although FA remains the gold standard for determining the presence of leakage and OCT easily shows fluid accumulation and its variations, OCT-A offers noninvasive monitoring of the retinal and choriocapillaris microvasculature in patients with CNV, aiding in diagnosis and treatment decisions during follow-up.
PURPOSE: To report the optical coherence tomography angiography (OCT-A) findings in an exudative age-related macular degeneration (AMD) patient presenting mixed type I and II choroidal neovascularization (CNV) during follow-up after intravitreal vascular endothelial growth factor (VEGF) trap treatment. METHODS: The clinical assessment included both traditional multimodal imaging, based on fluorescein angiography (FA), indocyanine green angiography (ICGA) and B-scan OCT, and OCT-A at baseline and follow-up. OCT-A images were obtained using a Spectralis OCT-A prototype able to acquire 70,000 A-scans per second, with a resolution of 7 µm axially and 14 µm laterally. An amplitude decorrelation algorithm developed by Heidelberg Engineering was applied to a volume scan, on a 15 × 5° area, which was composed of 131 B-scans (35 frames per scan) at a distance of 11 µm each. The borders of type I and type II CNV were manually outlined and then the areas were analyzed using the provided automated software before and after treatment. RESULTS: The qualitative approach revealed a substantial decrease in the visibility of tiny branching vessels and anastomoses both in type I and type II components of the neovascular complex, associated with persistence of a clear hyperintense signal coming from the larger trunks, which remained well-perfused. Quantitative analysis confirmed a reduction of the lesion area after VEGF trap treatment: the type II component decreased from 0.25 to 0.19 mm(2), while the type I component decreased from 2.03 to 1.80 mm(2). CONCLUSIONS: Our study qualitatively and quantitatively demonstrated the response of a mixed type I-II CNV to intravitreal VEGF trap therapy. Although FA remains the gold standard for determining the presence of leakage and OCT easily shows fluid accumulation and its variations, OCT-A offers noninvasive monitoring of the retinal and choriocapillaris microvasculature in patients with CNV, aiding in diagnosis and treatment decisions during follow-up.
Authors: Vaël Souedan; Eric H Souied; Violaine Caillaux; Alexandra Miere; Ala El Ameen; Rocio Blanco-Garavito Journal: Int Ophthalmol Date: 2017-05-25 Impact factor: 2.031
Authors: Carl B Rebhun; Eric M Moult; Stefan B Ploner; Carlos Moreira Neto; A Yasin Alibhai; Julia Schottenhamml; Byungkun Lee; WooJhon Choi; Fareed A Rifai; Mary W Tam; Lennart Husvogt; Caroline R Baumal; Andre J Witkin; Andreas Maier; Philip J Rosenfeld; Jay S Duker; James G Fujimoto; Nadia K Waheed Journal: Ophthalmol Retina Date: 2017-10-31
Authors: Eduardo A Novais; Mehreen Adhi; Eric M Moult; Ricardo N Louzada; Emily D Cole; Lennart Husvogt; ByungKun Lee; Sabin Dang; Caio V S Regatieri; André J Witkin; Caroline R Baumal; Joachim Hornegger; Vijaysekhar Jayaraman; James G Fujimoto; Jay S Duker; Nadia K Waheed Journal: Am J Ophthalmol Date: 2016-02-04 Impact factor: 5.258
Authors: Mehrdad Malihi; Yali Jia; Simon S Gao; Christina Flaxel; Andreas K Lauer; Thomas Hwang; David J Wilson; David Huang; Steven T Bailey Journal: Br J Ophthalmol Date: 2016-12-02 Impact factor: 4.638
Authors: Scott M McClintic; Simon Gao; Jie Wang; Ahmed Hagag; Andreas K Lauer; Christina J Flaxel; Kavita Bhavsar; Thomas S Hwang; David Huang; Yali Jia; Steven T Bailey Journal: Ophthalmol Retina Date: 2018-03-02